Nammi Therapeutics, Inc. is an immuno-oncology company based in Los Angeles that is developing platforms and products that selectively activate anti-tumor immunity within the tumor microenvironment while minimizing systemic activation. By reducing systemic activation of the immune system, Nammi expects to improve safety and enhance the ability to combine multiple immune modulators. Nammi’s lead product candidate, QXL138AM, is a Masked Immunocytokine (MIC) targeting a masked interferon to the tumor antigen, CD138. In addition to the MIC platform, Nammi has also developed a nanoparticle platform to deliver Immune Modulating Prodrugs (IMPs) using their Nammisome technology. Multiple Nammisome clinical candidates have also been selected for development.
External link for Nammi Therapeutics, Inc.
10940 WILSHIRE BLVD
STE 600
Los Angeles, CA 90024, US
Very excited for our first clinical trial!
Nammi Therapeutics, Inc. has posted details for a first-in-human Phase 1a/1b study of QXL138AM in participants with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma. QXL138AM is a masked immuno-cytokine comprised of an anti-CD138 IgG1 antibody fused to human interferon alpha 2a. The study is enrolling an estimated 100 participants. #immunocytokines #mAbs https://lnkd.in/dgPJjQaF
We are excited to announce this major milestone!